涂层葡萄糖微珠刺激肠道激素的释放,改善葡萄糖耐受性在第1期和第2期临床试验
Kai Deusch1,2,3, Arthur Deboek4, Christian Sina5,6
1Department of Physiology, University of Toronto, Toronto, Canada.
Diabetes, obesity & metabolism
|September 17, 2025
概括
口服微珠将葡萄糖输送到肠道,激活天然激素,以改善糖尿病前期患者的葡萄糖耐受性. 这种新的方法为肥胖等代谢障碍提供了安全有效的替代方案.
科学领域:
- 胃肠道学和新陈代谢学
- 药理学和药物输送 药理学和药物输送
- 内分泌学 在内分泌学.
背景情况:
- 胰岛素激动剂用于肥胖和代谢功能障碍,但由于系统性输送,可能会引起不良反应.
- 口服微珠配方提供了一种新的方法,通过远端营养感应细胞激活内源性肠内分泌信号.
研究的目的:
- 测试和优化口服微珠配方,以有针对性地将营养物质输送到远端小肠.
- 评估内源性肠内分泌信号的激活及其对葡萄糖耐受性的影响.
主要方法:
- 两个随机的第一阶段研究评估了对提供葡萄糖的微珠的药理动力学/药理动力学反应.
- 一个2a期试验评估了6周的糖尿病前期患者的配方,使用交叉设计.
- 主要终点包括血葡萄糖类1 (GLP-1) 水平和曲线下口服葡萄糖耐受性区域的变化.
主要成果:
- 微珠配方成功准了远端小肠,诱导了强大的肠内分泌反应.
- 配方显著改善了糖尿病前期患者的葡萄糖耐受性,与GLP-1模仿剂相比.
- 副作用是罕见的和轻微的.
结论:
- 通过微粒的向葡萄糖释放有效地激活内源性肠内分泌信号网络.
- 这种方法可以改善葡萄糖耐受性,并具有最小的不良影响,显示出治疗代谢障碍的潜力.
- 准原生肠内分泌信号是一种破坏性策略,用于管理肥胖和相关疾病.
相关概念视频
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Hormones Regulating Blood Glucose
6.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.5K
Glucose Absorption Into the Small Intestine
35.1K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
35.1K


